CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S. Dial-in Number: 833-634-2546
International Dial-in Number: 412-902-4190
All participants should ask to be connected to the Fulcrum Therapeutics conference call.
Replay U.S. Dial-in Number: 877-344-7529
Replay Canada Dial-In Number: 855-669-9658
Replay International Dial-in Number: 412-317-0088
Replay Access Code: 7096297
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.
Contacts:
Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200
Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324
Kwame Marfo brings more than 15 years of experience at the intersection of life sciences,…
EIRMAR, EirSystem’s electronic medication administration records platform, delivers advanced medication management functionality to help providers…
SALT LAKE CITY--(BUSINESS WIRE)--Echo, the global leader in hydrogen health technology, is responding forcefully to…
SALT LAKE CITY--(BUSINESS WIRE)--Echo, the global leader in hydrogen health technology, is responding forcefully to…
Investors choose to redeem or convert the majority of Series C and Series D Preferred…
LOUISVILLE, Ky., July 29, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of…